Overview TUC3PII-01_TU2670 Phase IIa Clinical Study Status: Recruiting Trial end date: 2023-12-31 Target enrollment: Participant gender: Summary This Protocol for TU2670 is to investigate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple doses of TU2670 in subjects with moderate to severe endometriosis-associated pain. Phase: Phase 2 Details Lead Sponsor: TiumBio Co., Ltd.